Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study
Nicole Ngai Yung Tsang, Hau Chi So, Benjamin J. Cowling, et al.
The Lancet Infectious Diseases (2022) Vol. 23, Iss. 4, pp. 421-434
Open Access | Times Cited: 52

Showing 1-25 of 52 citing articles:

Estimating the transmission dynamics of SARS-CoV-2 Omicron BF.7 in Beijing after adjustment of the zero-COVID policy in November–December 2022
Kathy Leung, Eric H. Y. Lau, Carlos King Ho Wong, et al.
Nature Medicine (2023) Vol. 29, Iss. 3, pp. 579-582
Open Access | Times Cited: 137
Damage to endothelial barriers and its contribution to long COVID
Xiaoming Wu, Mengqi Xiang, Haijiao Jing, et al.
Angiogenesis (2023) Vol. 27, Iss. 1, pp. 5-22
Open Access | Times Cited: 43
Safety, immunogenicity and efficacy of the self-amplifying mRNA ARCT-154 COVID-19 vaccine: pooled phase 1, 2, 3a and 3b randomized, controlled trials
Nhân Thị Hồ, Steven G. Hughes, Van Thanh Ta, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 24
Broad-spectrum pan-genus and pan-family virus vaccines
Chee Wah Tan, Sophie Valkenburg, Leo L. M. Poon, et al.
Cell Host & Microbe (2023) Vol. 31, Iss. 6, pp. 902-916
Open Access | Times Cited: 22
What makes SARS‐CoV‐2 unique? Focusing on the spike protein
Jingbo Qian, Shi-Chang Zhang, Fang Wang, et al.
Cell Biology International (2024) Vol. 48, Iss. 4, pp. 404-430
Open Access | Times Cited: 12
Altered receptor binding, antibody evasion and retention of T cell recognition by the SARS-CoV-2 XBB.1.5 spike protein
Dhiraj Mannar, James W. Saville, Chad Poloni, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 8
Population-Based Evaluation of Vaccine Effectiveness against SARS-CoV-2 Infection, Severe Illness, and Death, Taiwan
Cheng-Yi Lee, Hung-Wei Kuo, Yulun Liu, et al.
Emerging infectious diseases (2024) Vol. 30, Iss. 3
Open Access | Times Cited: 7
Long-Term Safety Analysis of the ChAdOx1-nCoV-19 Corona Virus Vaccine: Results from a Prospective Observational Study in Priority Vaccinated Groups in North India
Upinder Kaur, Zeba Fatima, Kalika Maheshwari, et al.
Drug Safety (2023) Vol. 46, Iss. 6, pp. 553-563
Open Access | Times Cited: 15
Wastewater Surveillance Provides Spatiotemporal SARS-CoV-2 Infection Dynamics
Xiawan Zheng, Kathy Leung, Xiaoqing Xu, et al.
Engineering (2024) Vol. 40, pp. 70-77
Open Access | Times Cited: 6
COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 BA.1/BA.2 lineages among adults and adolescents in a multicentre primary care study, Europe, December 2021 to June 2022
Charlotte Lanièce Delaunay, Iván Martínez‐Baz, Noémie Sève, et al.
Eurosurveillance (2024) Vol. 29, Iss. 13
Open Access | Times Cited: 6
The effect of COVID-19 vaccine to the Omicron variant in children and adolescents: a systematic review and meta-analysis
Wenting Lu, Shuai Zeng, Yuan Yao, et al.
Frontiers in Public Health (2024) Vol. 12
Open Access | Times Cited: 6
Impact of SARS-CoV-2 inactivated vaccine on symptoms following omicron variant breakthrough infection
Yuqi Zhang, Xinjie Li, Yingxiang Yang, et al.
Vaccine (2025) Vol. 48, pp. 126722-126722
Closed Access
Comparative Study of Humoral Immunity Against SARS-CoV-2 Induced by Different COVID-19 Vaccine Types: Insights into Protection Against Wild-Type, Delta and JN.1 Omicron Strains
Zahra Hasan, Kiran Iqbal Masood, Shama Qaiser, et al.
(2025)
Closed Access
Systemic immune profiling of Omicron-infected subjects inoculated with different doses of inactivated virus vaccine
Shanhe Yu, Yingni Lin, Yong Li, et al.
Cell (2023) Vol. 186, Iss. 21, pp. 4615-4631.e16
Open Access | Times Cited: 13
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial
Gustavo H. Dayan, Nadine Rouphael, Stephen R. Walsh, et al.
The Lancet Respiratory Medicine (2023) Vol. 11, Iss. 11, pp. 975-990
Open Access | Times Cited: 12
Investigating incidence of and factors associated with SARS-CoV-2 infection over a nine-month period in a highly-vaccinated healthcare worker cohort
Liam Townsend, Louise Marron, Katie M. O’Brien, et al.
QJM (2024) Vol. 117, Iss. 9, pp. 638-646
Closed Access | Times Cited: 4
P21-activated kinase 1 (PAK1)-mediated cytoskeleton rearrangement promotes SARS-CoV-2 entry and ACE2 autophagic degradation
Ming Liu, Bingtai Lu, Yue Li, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 11
Comparative antibody and cell-mediated immune responses, reactogenicity, and efficacy of homologous and heterologous boosting with CoronaVac and BNT162b2 (Cobovax): an open-label, randomised trial
Nancy Leung, Samuel M. S. Cheng, Carolyn A. Cohen, et al.
The Lancet Microbe (2023) Vol. 4, Iss. 9, pp. e670-e682
Open Access | Times Cited: 10
Explosive household spread of the SARS-CoV-2 Omicron variant in China in late 2022
Nan Zhang, Yong Guo, Benjamin J. Cowling, et al.
Building and Environment (2024) Vol. 256, pp. 111491-111491
Closed Access | Times Cited: 3
Effectiveness of the booster dose of inactivated COVID-19 vaccine against Omicron BA.5 infection: a matched cohort study of adult close contacts
Ting Zeng, Yaoqin Lu, Yanji Zhao, et al.
Respiratory Research (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 9
Have Diagnostics, Therapies, and Vaccines Made the Difference in the Pandemic Evolution of COVID-19 in Comparison with “Spanish Flu”?
Florigio Lista, Mario Stefano Peragallo, Roberto Biselli, et al.
Pathogens (2023) Vol. 12, Iss. 7, pp. 868-868
Open Access | Times Cited: 8
Booster vaccines dose reduced mortality in hospitalized COVID-19 patients requiring oxygen supplementation: Evidence from the Beijing Omicron outbreak
Xinrui Wang, Yi Zhang, Chong Huang, et al.
Human Vaccines & Immunotherapeutics (2024) Vol. 20, Iss. 1
Open Access | Times Cited: 2
Antibody Fc receptor binding and T cell responses to homologous and heterologous immunization with inactivated or mRNA vaccines against SARS-CoV-2
Carolyn A. Cohen, Nancy Leung, Prathanporn Kaewpreedee, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 2
Effectiveness of inactivated COVID-19 vaccines in preventing COVID-19-related hospitalization during the Omicron BF.7-predominant epidemic wave in Beijing, China: a cohort study
Dan Zhao, Ying Sun, Juan Li, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 2
Early Omicron infection is associated with increased reinfection risk in older adults in long-term care and retirement facilities
Jessica A. Breznik, Ahmad Rahim, Ali Zhang, et al.
EClinicalMedicine (2023) Vol. 63, pp. 102148-102148
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top